These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8787077)

  • 1. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
    Siegall CB
    Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
    Friedman PN; Chace DF; Trail PA; Siegall CB
    J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
    Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
    J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
    Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
    J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
    Siegall CB
    Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
    Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.
    Friedman PN; McAndrew SJ; Gawlak SL; Chace D; Trail PA; Brown JP; Siegall CB
    Cancer Res; 1993 Jan; 53(2):334-9. PubMed ID: 8417827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
    Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
    Chiron MF
    Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-tumoral application of a heregulin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects.
    Groner B; Wick B; Jeschke M; Fiebig HH; Dengler W; Runau T; Mihatsch M; Kahl R; Schmidt M; Wels W; Stöcklin E
    Int J Cancer; 1997 Mar; 70(6):682-7. PubMed ID: 9096650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.
    Siegall CB; Bacus SS; Cohen BD; Plowman GD; Mixan B; Chace D; Chin DM; Goetze A; Green JM; Hellström I
    J Biol Chem; 1995 Mar; 270(13):7625-30. PubMed ID: 7535774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells.
    Akamatsu Y; Murphy JC; Nolan KF; Thomas P; Kreitman RJ; Leung SO; Junghans RP
    Clin Cancer Res; 1998 Nov; 4(11):2825-32. PubMed ID: 9829749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
    Siegall CB; Liggitt D; Chace D; Mixan B; Sugai J; Davidson T; Steinitz M
    Clin Cancer Res; 1997 Mar; 3(3):339-45. PubMed ID: 9815690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications.
    Wu T; Zhu J
    Int Immunopharmacol; 2021 Jul; 96():107759. PubMed ID: 34162138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
    Arteaga CL; Hurd SD; Dugger TC; Winnier AR; Robertson JB
    Cancer Res; 1994 Sep; 54(17):4703-9. PubMed ID: 8062268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
    Siegall CB; Liggitt D; Chace D; Tepper MA; Fell HP
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9514-8. PubMed ID: 7937798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
    Posey JA; Khazaeli MB; Bookman MA; Nowrouzi A; Grizzle WE; Thornton J; Carey DE; Lorenz JM; Sing AP; Siegall CB; LoBuglio AF; Saleh MN
    Clin Cancer Res; 2002 Oct; 8(10):3092-9. PubMed ID: 12374676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-chain immunotoxins targeted to CD40 for the treatment of human B-lineage hematologic malignancies.
    Francisco JA; Siegall CB
    Leuk Lymphoma; 1998 Jul; 30(3-4):237-45. PubMed ID: 9713956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of dichotomous action of IL-2-Pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response.
    Volk HD; Müller S; Yarkoni S; Diamantstein T; Lorberboum-Galski H
    J Immunol; 1994 Sep; 153(6):2497-505. PubMed ID: 8077661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.